(ENTA/PRDS/etc)—SRNE says its SARS-CoV-2 protease inhibitor won’t need ritonavir boosting: https://www.globenewswire.com/news-release/2022/01/28/2375086/0/en/Sorrento-Announces-Its-Oral-SARS-CoV-2-Main-Protease-Mpro-Inhibitor-STI-1558-Strongly-Neutralizes-Omicron.html SRNE could be a serious competitor. On the other hand, SRNE has a history of making big claims.